ArticleNucleic acids research2013
A comprehensive approach to zinc-finger recombinase customization enables genomic targeting in human cells.
Article in Nucleic acids research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Programmable enzymes for targeted gene insertion.Nature reviews. Genetics · 2026Review
- Retargeted serine integrases for one-step, precise integration of large DNA sequences in human cells.Nature biotechnology · 2026Article
- Advancements in genome editing tools for genetic studies and crop improvement.Frontiers in plant science · 2024Review
- Pairing of single mutations yields obligate Cre-type site-specific recombinases.Nucleic acids research · 2022Article
- RNA-Guided Recombinase-Cas9 Fusion Targets Genomic DNA Deletion and Integration.The CRISPR journal · 2019Article
- Engineering altered protein-DNA recognition specificity.Nucleic acids research · 2018Review
- Beyond editing to writing large genomes.Nature reviews. Genetics · 2017Article
- Engineering and Application of Zinc Finger Proteins and TALEs for Biomedical Research.Molecules and cells · 2017Review
- The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia.Oncotarget · 2017Article
- Genome-Editing Technologies: Principles and Applications.Cold Spring Harbor perspectives in biology · 2016Review
- A programmable Cas9-serine recombinase fusion protein that operates on DNA sequences in mammalian cells.Nucleic acids research · 2016Article
- Selection platforms for directed evolution in synthetic biology.Biochemical Society transactions · 2016Review
- Human Induced Pluripotent Stem Cells as a Platform for Personalized and Precision Cardiovascular Medicine.Physiological reviews · 2016Review
- The Development of TALE Nucleases for Biotechnology.Methods in molecular biology (Clifton, N.J.) · 2016Article
- Article
- Recent advances in developing molecular tools for targeted genome engineering of mammalian cells.BMB reports · 2015Review
- Synthetic zinc finger proteins: the advent of targeted gene regulation and genome modification technologies.Accounts of chemical research · 2014Article
- Enhancing the specificity of recombinase-mediated genome engineering through dimer interface redesign.Journal of the American Chemical Society · 2014Article
- Expanding the zinc-finger recombinase repertoire: directed evolution and mutational analysis of serine recombinase specificity determinants.Nucleic acids research · 2014Article
- Expanding the scope of site-specific recombinases for genetic and metabolic engineering.Biotechnology and bioengineering · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Zinc-finger recombinases (ZFRs) represent a potentially powerful class of tools for targeted genetic engineering. These chimeric enzymes are composed of an activated catalytic domain derived from the resolvase/invertase family of serine recombinases and a custom-designed zinc-finger DNA-binding domain. The use of ZFRs, however, has been restricted by sequence requirements imposed by the recombinase catalytic domain. Here, we combine substrate specificity analysis and directed evolution to develop a diverse collection of Gin recombinase catalytic domains capable of recognizing an estimated 3.77 × 10(7) unique DNA sequences. We show that ZFRs assembled from these engineered catalytic domains recombine user-defined DNA targets with high specificity, and that designed ZFRs integrate DNA into targeted endogenous loci in human cells. This study demonstrates the feasibility of generating customized ZFRs and the potential of ZFR technology for a diverse range of applications, including genome engineering, synthetic biology and gene therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.